China-based Cytocraft Biotech Development has announced that its cell therapy, SDT-T002, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of advanced liver cancer that has failed standard treatment.
Cascade Primed Immune Cells (CAPRI) Cell Therapy Overview
Cytocraft boasts its Cascade Primed Immune Cells (CAPRI) cell therapy, a treatment that utilizes the peripheral blood lymphocytes of tumor patients. After activation and stimulation, these cells gain specific killing function against tumors and are capable of killing tumor cells in vivo after reinfusion. This innovative therapy has the potential to complement traditional therapies such as radiotherapy and chemotherapy, extending the survival period of tumor patients and improving their quality of life.
Clinical Therapeutic Effects and Applications
The therapy has demonstrated clinical therapeutic effects in a range of cancers, including non-Hodgkin’s lymphoma, lung cancer, stomach cancer, bowel cancer, brain tumor, breast cancer, ovarian cancer, and prostate cancer in Germany. The approval of SDT-T002 by the NMPA marks a significant step forward in providing advanced liver cancer patients with an additional treatment option that leverages the body’s immune system to combat cancer.-Fineline Info & Tech
